Sign in

Deborah J. Lucas

Director at CME
Board

About Deborah J. Lucas

Independent director since 2018; age 66. Sloan Distinguished Professor of Finance at MIT Sloan (since 2011) and Director of the MIT Golub Center for Finance and Policy (since 2012). Prior government and academic leadership roles include Chief Economist and assistant/associate director at the Congressional Budget Office, senior staff economist at the Council of Economic Advisers, and professor at Northwestern’s Kellogg School. Current affiliations include advisory board member (Urban Institute), trustee (NBER pension plans), associate editor (Annual Review of Financial Economics), member (Shadow Open Market Committee), and visiting scholar at the IMF. She also serves on the board of P/E Investments (private) and NatureServe (non-profit). Classified by CME as both independent and a CFTC “public director.”

Past Roles

OrganizationRoleTenureCommittees/Impact
Congressional Budget OfficeChief Economist; assistant/associate directorPrior roles (dates not specified) Developed strategies for analysis of costs/risks of federal credit/guarantee activities; testified before Congress
Council of Economic AdvisersSenior staff economistPrior role (dates not specified) Macroeconomic/financial policy analysis
Northwestern University (Kellogg)ProfessorPrior role (dates not specified) Academic leadership and research
Federal Home Loan Bank of ChicagoIndependent director (prior)Prior role (dates not specified) Board oversight in a regulated financial institution

External Roles

OrganizationRoleTenure/StatusNotes
MIT Sloan School of ManagementSloan Distinguished Professor of FinanceSince 2011 Teaches futures/options and fixed income/derivatives
MIT Golub Center for Finance & PolicyDirectorSince 2012 Research on government financial institutions/policy
Urban InstituteAdvisory Board MemberCurrent Public policy advisory
NBERTrustee (pension plans)Current Fiduciary oversight
Annual Review of Financial EconomicsAssociate EditorCurrent Editorial/academic governance
Shadow Open Market CommitteeMemberCurrent Monetary policy expertise
International Monetary FundVisiting ScholarCurrent Global financial policy research
P/E InvestmentsBoard memberCurrent Privately held asset manager
NatureServeBoard memberCurrent Non-profit governance

Board Governance

ItemDetail
IndependenceBoard determined all current directors are independent except the CEO; Lucas is independent. CME also classifies her as a CFTC “public director,” strengthening conflict-of-interest controls and market oversight.
CommitteesAudit (member) ; Clearing House Oversight (member; 8 meetings in 2024) ; Finance (member; 5 meetings in 2024) ; Market Regulation Oversight (member; 6 meetings in 2024)
AttendanceBoard held six regular and one special meeting in 2024; each director attended >75% of combined board and committee meetings. Average committee attendance was 99% across 52 meetings.
Public Director RoleMarket Regulation Oversight Committee is composed solely of public directors; Lucas serves on it, reinforcing regulatory independence.
Governance PracticesAnti-hedging and anti-pledging policy for directors; meaningful stock ownership guidelines; majority voting for equity directors; quarterly executive sessions led by Lead Independent Director; 100% independence across principal standing committees.

Fixed Compensation

Component (2024)Amount
Fees Earned or Paid in Cash$150,500
Stock Awards (grant-date fair value)$145,187 (one annual grant; closing price used $194.10 on June 25, 2024; not subject to vesting)
All Other Compensation$0
Total$295,687

Director pay structure (standard elements for 2024):

  • Annual cash stipend: $95,000
  • Annual equity stipend: $145,000 (directors may elect to receive additional shares in lieu of cash; awards under Director Stock Plan, not subject to vesting)
  • Committee membership retainer: $12,000; Committee chair retainer: $25,000; Lead Director stipend: $50,000; functional committee meeting fees: $1,000–$1,250
  • Deferred Compensation Plan available; no pensions/health benefits for non-executive directors; returns only based on selected market investments

Performance Compensation

Directors do not receive performance-based equity and awards are not subject to vesting restrictions; no options or performance share metrics apply to non-executive directors.

ElementPerformance-linked?Evidence
Annual equity stipend (directors)NoAwards not subject to vesting restrictions; no other awards to non-executive directors in 2024
Options/PSUs for directorsNoDirector Stock Plan provides equity but table shows only stock awards; no options/performance awards granted in 2024

Other Directorships & Interlocks

Company/InstitutionTypeRoleNotes
Federal Home Loan Bank of ChicagoPublic (prior)Independent director (prior)Historical public board experience in a regulated institution
P/E InvestmentsPrivateBoard memberAsset management; no related-party transactions disclosed by CME
NatureServeNon-profitBoard memberConservation data non-profit; no conflicts disclosed
  • CME restricts non-employee directors from serving on more than four public company boards, enhancing bandwidth and independence; no current public company directorships for Lucas are disclosed in the last five years.

Expertise & Qualifications

  • Deep financial economics expertise and derivatives knowledge; teaches futures/options and fixed income/derivatives; research on government guarantees and systemic risk.
  • Government policy and regulatory experience (CBO, CEA); frequent Congressional testimony on housing finance, student loans, and SIFIs.
  • Academic leadership (MIT Sloan; Golub Center); editorial and scholarly governance roles (Annual Review; NBER; Shadow Open Market Committee).
  • Classified as “public director,” augmenting CME’s oversight of market regulation and conflicts.

Equity Ownership

ItemDetail
Class A shares beneficially owned (Lucas)4,856
Class B sharesNone disclosed for Lucas
Ownership % of any classNone of directors/NEOs own more than 1% of any class (as of March 10, 2025)
Director ownership guidelinesRequired holding equals 2× total annual retainer (2024 guideline value: $480,000); each director has five years to comply. CME disclosed all directors with ≥5 years of service met the guideline; Lucas has seven years of service (since 2018).
Hedging/PledgingDirectors prohibited from hedging CME stock; pledging prohibited, with any waivers disclosed. As of latest disclosure, no directors have pledged shares.

Governance Assessment

  • Board effectiveness: Lucas’ breadth across Audit, Clearing House Oversight, Finance, and Market Regulation Oversight places her at the core of CME’s risk, regulatory, financial, and disclosure oversight—high-value coverage for a systemically important market infrastructure.
  • Independence and conflicts: Classified independent and “public director”; CME’s related-party policy pre-approves ordinary-course trading/market data and requires audit committee approval for any other related-party transactions—no Lucas-specific related-party transactions disclosed.
  • Engagement and attendance: Each director attended >75% of meetings; committees held 52 meetings with 99% average attendance, indicating strong engagement.
  • Ownership alignment: Material stock ownership guidelines and prohibition on hedging/pledging support alignment; Lucas holds 4,856 Class A shares and, based on tenure, falls within the cohort meeting guidelines.
  • Director pay structure: Mix of cash and fixed equity; no performance-contingent director awards; directors may elect stock in lieu of cash, enabling greater skin-in-the-game without adding risk of pay-for-performance distortions at the board level.
  • Company-level signals: Following board-led outreach, say-on-pay support improved to 87% in 2024—an indicator of responsive governance; board continues multi-year refresh and maintains majority-independent structure with robust committee architecture.

RED FLAGS: None disclosed specific to Lucas. No hedging/pledging, no related-party transactions, and strong public director classification mitigate conflict risk.

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%